Fosamax and Osteonecrosis of the Jaw: Understanding the Link and FDA Warnings

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Targeted Risk Awareness

For decades, public health communication has centered on broad wellness principles, emphasizing preventive care and the management of common chronic conditions. Within this legacy framework, general health information has served as a foundation for patient awareness, often focusing on lifestyle factors and medication adherence without delving into specialized risks. As the domain of mass production evolves, however, the need arises to translate this general health literacy into more targeted contexts—specifically, those involving occupational or environmental exposures. The transition from a universal health perspective to a focused concern about specific pharmaceutical agents requires careful bridging. In this case, the legacy of general health science provides the baseline understanding of bone health and medication use, which now must be reframed to address emerging safety signals. The pivot occurs when we consider how routine exposure to certain compounds, such as bisphosphonates like Fosamax, may introduce distinct risk profiles that were not prominent in earlier public health messaging. This shift does not imply a rejection of prior knowledge but rather an expansion of the health information framework to accommodate new evidence on exposure-related outcomes. By maintaining the neutral, evidence-informed tone of the legacy heritage, we can now direct attention to the specific intersection of pharmaceutical exposure and oral health complications, setting the stage for a more detailed examination of occupational risk factors.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the general understanding of bone health and medication use, we now focus on Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Risk Factors for Fosamax-Associated ONJ

Mechanistic pathways linking Fosamax to ONJ involve the drug's effects on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast activity, reducing bone turnover. This suppression of normal bone repair may contribute to the development of ONJ, particularly in the jawbone, which undergoes frequent remodeling due to dental procedures and mechanical stress. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique biology of the jawbone, which may make it more susceptible to bisphosphonate-related complications. Risk assessment tools are being developed to predict ONJ risk. One study introduced the concepts of equivalent dose (ED) and threshold dose (TD) as predictive risk assessment tools for medication-related osteonecrosis of the jaw (MRONJ) (https://pubmed.ncbi.nlm.nih.gov/40619534/). In this study, ED for each medication was standardized to the cumulative dose of four years of weekly oral alendronate use (14,560 mg) (https://pubmed.ncbi.nlm.nih.gov/40619534/). This approach may help clinicians identify patients at higher risk for ONJ based on their cumulative bisphosphonate exposure.

Clinical Management and Causation Considerations

For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This recommendation is based on the understanding that bisphosphonate accumulation in bone can impair healing after dental surgery. However, the decision to discontinue therapy should be made in consultation with the prescribing physician, weighing the benefits of osteoporosis treatment against the potential risk of ONJ. Causation considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ, as well as ruling out other potential causes. The timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ after starting Fosamax, particularly those with no other known risk factors, may have a stronger case for causation. However, the presence of other risk factors, such as invasive dental procedures or cancer therapy, complicates the assessment. The adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information. The label includes a specific warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also describes known risk factors and recommends discontinuation of bisphosphonate treatment before invasive dental procedures to reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide clinicians and patients with information to make informed decisions about treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the FDA warning regarding Fosamax and osteonecrosis of the jaw?

The FDA has issued a warning that Fosamax (alendronate) and other bisphosphonates are associated with an increased risk of osteonecrosis of the jaw (ONJ). The prescribing information includes a specific warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also describes known risk factors such as invasive dental procedures, cancer, and poor oral hygiene, and recommends discontinuation of bisphosphonate treatment before invasive dental procedures to reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast activity, reducing bone turnover. This suppression of normal bone repair may contribute to the development of ONJ, particularly in the jawbone, which undergoes frequent remodeling due to dental procedures and mechanical stress. Research has shown that the jawbone has unique biological properties that may make it more susceptible to bisphosphonate-related complications (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate exposure.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.